Cargando…

p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies

BACKGROUND: The effect of the p.Arg72Pro variant of the P53 gene on the risk of development ofbreast cancer remains variable in populations. However, the use ofstrategies such aspoolingage-matched controls with disease may provide a consistent meta-analysis. Our goal was to perform a meta-analysis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Diakite, Brehima, Kassogue, Yaya, Dolo, Guimogo, Wang, Jun, Neuschler, Erin, Kassogue, Oumar, Keita, Mamadou L, Traore, Cheick B, Kamate, Bakarou, Dembele, Etienne, Nadifi, Sellama, Murphy, Robert L, Doumbia, Seydou, Hou, Lifang, Maiga, Mamoudou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574232/
https://www.ncbi.nlm.nih.gov/pubmed/33076844
http://dx.doi.org/10.1186/s12881-020-01133-8
_version_ 1783597599652052992
author Diakite, Brehima
Kassogue, Yaya
Dolo, Guimogo
Wang, Jun
Neuschler, Erin
Kassogue, Oumar
Keita, Mamadou L
Traore, Cheick B
Kamate, Bakarou
Dembele, Etienne
Nadifi, Sellama
Murphy, Robert L
Doumbia, Seydou
Hou, Lifang
Maiga, Mamoudou
author_facet Diakite, Brehima
Kassogue, Yaya
Dolo, Guimogo
Wang, Jun
Neuschler, Erin
Kassogue, Oumar
Keita, Mamadou L
Traore, Cheick B
Kamate, Bakarou
Dembele, Etienne
Nadifi, Sellama
Murphy, Robert L
Doumbia, Seydou
Hou, Lifang
Maiga, Mamoudou
author_sort Diakite, Brehima
collection PubMed
description BACKGROUND: The effect of the p.Arg72Pro variant of the P53 gene on the risk of development ofbreast cancer remains variable in populations. However, the use ofstrategies such aspoolingage-matched controls with disease may provide a consistent meta-analysis. Our goal was to perform a meta-analysis in order to assess the association of p.Arg72Pro variant of P53 gene with the risk of breast cancer. METHODS: Databases such as PubMed, Genetics Medical Literature, Harvard University Library, Web of Science and Genesis Library were used to search articles. Case-control studies with age-matched on breast cancer havingevaluated the genotype frequencies of the TP53 p.Arg72Pro polymorphism were selected. The fixed and random effects (Mantel-Haenszel) were calculated using pooled odds ratio of 95% CI to determine the risk of disease. Inconsistency was calculated to determine heterogeneity among the studies. The publication bias was estimated using the funnel plot. RESULTS: Twenty-one publications with 7841 cases and 8876 controls were evaluated in this meta-analysis. Overall, our results suggested that TP53 p.Arg72Pro was associated with the risk of breast cancer for the dominant model (OR = 1.09, 95% CI = 1.02–1.16, P = 0.01) and the additive model (OR = 1.09, 95% CI = 1.01–1.17, P = 0.03), but not for the recessive model (OR = 1.07, 95% CI = 0.97–1.18, P = 0.19). According to the ethnic group analysis, Pro allele was associated with the risk of breast cancer in Caucasians for the dominant model and additive model (P = 0.02), and Africans for the recessive model and additive model (P = 0.03). CONCLUSIONS: This meta-analysis found a significant association between TP53 p.Arg72Pro polymorphism and the risk of breast cancer. Individuals carrying at least one Pro allele were more likely to have breast cancer than individuals harboring the Arg allele.
format Online
Article
Text
id pubmed-7574232
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75742322020-10-20 p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies Diakite, Brehima Kassogue, Yaya Dolo, Guimogo Wang, Jun Neuschler, Erin Kassogue, Oumar Keita, Mamadou L Traore, Cheick B Kamate, Bakarou Dembele, Etienne Nadifi, Sellama Murphy, Robert L Doumbia, Seydou Hou, Lifang Maiga, Mamoudou BMC Med Genet Research Article BACKGROUND: The effect of the p.Arg72Pro variant of the P53 gene on the risk of development ofbreast cancer remains variable in populations. However, the use ofstrategies such aspoolingage-matched controls with disease may provide a consistent meta-analysis. Our goal was to perform a meta-analysis in order to assess the association of p.Arg72Pro variant of P53 gene with the risk of breast cancer. METHODS: Databases such as PubMed, Genetics Medical Literature, Harvard University Library, Web of Science and Genesis Library were used to search articles. Case-control studies with age-matched on breast cancer havingevaluated the genotype frequencies of the TP53 p.Arg72Pro polymorphism were selected. The fixed and random effects (Mantel-Haenszel) were calculated using pooled odds ratio of 95% CI to determine the risk of disease. Inconsistency was calculated to determine heterogeneity among the studies. The publication bias was estimated using the funnel plot. RESULTS: Twenty-one publications with 7841 cases and 8876 controls were evaluated in this meta-analysis. Overall, our results suggested that TP53 p.Arg72Pro was associated with the risk of breast cancer for the dominant model (OR = 1.09, 95% CI = 1.02–1.16, P = 0.01) and the additive model (OR = 1.09, 95% CI = 1.01–1.17, P = 0.03), but not for the recessive model (OR = 1.07, 95% CI = 0.97–1.18, P = 0.19). According to the ethnic group analysis, Pro allele was associated with the risk of breast cancer in Caucasians for the dominant model and additive model (P = 0.02), and Africans for the recessive model and additive model (P = 0.03). CONCLUSIONS: This meta-analysis found a significant association between TP53 p.Arg72Pro polymorphism and the risk of breast cancer. Individuals carrying at least one Pro allele were more likely to have breast cancer than individuals harboring the Arg allele. BioMed Central 2020-10-19 /pmc/articles/PMC7574232/ /pubmed/33076844 http://dx.doi.org/10.1186/s12881-020-01133-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Diakite, Brehima
Kassogue, Yaya
Dolo, Guimogo
Wang, Jun
Neuschler, Erin
Kassogue, Oumar
Keita, Mamadou L
Traore, Cheick B
Kamate, Bakarou
Dembele, Etienne
Nadifi, Sellama
Murphy, Robert L
Doumbia, Seydou
Hou, Lifang
Maiga, Mamoudou
p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies
title p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies
title_full p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies
title_fullStr p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies
title_full_unstemmed p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies
title_short p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies
title_sort p.arg72pro polymorphism of p53 and breast cancer risk: a meta-analysis of case-control studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574232/
https://www.ncbi.nlm.nih.gov/pubmed/33076844
http://dx.doi.org/10.1186/s12881-020-01133-8
work_keys_str_mv AT diakitebrehima parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT kassogueyaya parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT dologuimogo parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT wangjun parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT neuschlererin parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT kassogueoumar parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT keitamamadoul parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT traorecheickb parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT kamatebakarou parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT dembeleetienne parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT nadifisellama parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT murphyrobertl parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT doumbiaseydou parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT houlifang parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies
AT maigamamoudou parg72propolymorphismofp53andbreastcancerriskametaanalysisofcasecontrolstudies